Critical Limb Ischemia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 121 pages | ID: CF25963B2BAEEN
VPAResearch

Abstracts

2020 Critical Limb Ischemia PIPELINE HIGHLIGHTS
Critical Limb Ischemia is one of the widely researched conditions during 2020 with 27 companies actively focusing on realizing pipeline’s potential. Development of Critical Limb Ischemia medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Critical Limb Ischemia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Critical Limb Ischemia.

Good progress is anticipated during 2020 and 2021 with Critical Limb Ischemia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Critical Limb Ischemia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Critical Limb Ischemia DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Critical Limb Ischemia pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Critical Limb Ischemia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Critical Limb Ischemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Critical Limb Ischemia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Critical Limb Ischemia DRUG PROFILES
Critical Limb Ischemia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Critical Limb Ischemia COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Critical Limb Ischemia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Critical Limb Ischemia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 27 Critical Limb Ischemia companies including company overview, key snapshot, contact information, and their strategies on accelerating Critical Limb Ischemia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Anaeropharma Science Inc , Antidote Therapeutics Inc, Apceth Biopharma GmbH, Athersys Inc, BiogenCell Ltd , Biotech Holdings, Caladrius Biosciences Inc, Constant Therapeutics LLC, Cynata Therapeutics Limited, Gurus BioPharm LLC, Helixmith Co Ltd, Hemostemix Inc, ID Pharma Co Ltd , Juventas Therapeutics Inc , Libella Gene Therapeutics, LifeCells LLC, Pharmicell Co Ltd, Pluristem Therapeutics Inc, ReNeuron Group plc, Reven Pharmaceuticals Inc, Rexgenero Ltd, TaiGen Biotechnology Co Ltd , Taiwan Bio Therapeutics Co Ltd, Theratome Bio Inc, U.S. Stem Cell Inc , VESSL Therapeutics Ltd., ViroMed Co Ltd

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Critical Limb Ischemia
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO CRITICAL LIMB ISCHEMIA

1.1 Critical Limb Ischemia- Disease overview
1.2 Critical Limb Ischemia- Market Size
1.3 Critical Limb Ischemia- Companies Involved

2. CRITICAL LIMB ISCHEMIA PIPELINE SNAPSHOT- 2020

2.1 Critical Limb Ischemia Pipeline by Phase
2.2 Critical Limb Ischemia Pipeline by Mechanism of Action
2.3 Critical Limb Ischemia Pipeline by Route of Administration
2.4 Critical Limb Ischemia Pipeline- New Molecular Entities
2.5 Critical Limb Ischemia Pipeline- Orphan Drug Designation/ Special Designation

3. CRITICAL LIMB ISCHEMIA DRUG PROFILES

3.1 Current Status
3.2 Critical Limb Ischemia Drug Snapshot
3.3 Critical Limb Ischemia Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Anaeropharma Science Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.2 Antidote Therapeutics Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.3 Apceth Biopharma GmbH Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.4 Athersys Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.5 BiogenCell Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.6 Biotech Holdings Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.7 Caladrius Biosciences Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.8 Constant Therapeutics LLC Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.9 Cynata Therapeutics Limited Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.10 Gurus BioPharm LLC Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.11 Helixmith Co Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.12 Hemostemix Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.13 ID Pharma Co Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.14 Juventas Therapeutics Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.15 Libella Gene Therapeutics Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.16 LifeCells LLC Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.17 Pharmicell Co Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.18 Pluristem Therapeutics Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.19 ReNeuron Group plc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.20 Reven Pharmaceuticals Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.21 Rexgenero Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.22 TaiGen Biotechnology Co Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.23 Taiwan Bio Therapeutics Co Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.24 Theratome Bio Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.25 U.S. Stem Cell Inc Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.26 VESSL Therapeutics Ltd. Critical Limb Ischemia Pipeline Insights and Clinical Trials
4.27 ViroMed Co Ltd Critical Limb Ischemia Pipeline Insights and Clinical Trials

5. CRITICAL LIMB ISCHEMIA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information